3,480
Views
17
CrossRef citations to date
0
Altmetric
Editorial

COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management

, , , , ORCID Icon, , , & show all
Pages 959-964 | Received 14 Apr 2020, Accepted 25 Jun 2020, Published online: 02 Jul 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jaykaran Charan, Siddhartha Dutta, Rimplejeet Kaur, Pankaj Bhardwaj, Praveen Sharma, Sneha Ambwani, Iffat Jahan, Abdullahi Rabiu Abubakar, Salequl Islam, Timothy Craig Hardcastle, Nor Azlina A Rahman, Halyna Lugova & Mainul Haque. (2021) Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. Expert Opinion on Drug Safety 20:9, pages 1125-1136.
Read now

Articles from other publishers (16)

Tatjana Adzic-Vukicevic, Dejan Markovic, Aleksandar Reljic & Voin Brkovic. (2023) What did we learn about tocilizumab use against COVID-19? A single-center observational study from an intensive care unit in Serbia. Frontiers in Medicine 10.
Crossref
Vidhya Rajalakshmi V.Akilandeswari Ramu, Jayaprakash Chinnappan, Palanivel Velmurugan, Rajiv Pathak, Rami Adel Pashameah, Atif Abdulwahab A. Oyouni, Osama M. Al-Amer, Mohammed I. Alasseiri, Abdullah Hamadi, Mansuor A. Alanazi & Thangavelu Sathiamoorthi. (2023) Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology. PLOS ONE 18:3, pages e0282263.
Crossref
Riccardo Picasso, Andrea Cozzi, Virginia Picasso, Federico Zaottini, Federico Pistoia, Sara Perissi & Carlo Martinoli. (2023) Immune checkpoint inhibitor-related pneumonitis and COVID-19: a case-matched comparison of CT findings. La radiologia medica 128:2, pages 212-221.
Crossref
Haris Hatic, Kristine R. Hearld, Devika Das & Jessy Deshane. (2022) Clinical Outcomes in COVID-19 Patients Treated with Immunotherapy. Cancers 14:23, pages 5954.
Crossref
Haoran Li, Kamal K. Sahu & Benjamin L. Maughan. (2022) Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. Cancers 14:10, pages 2460.
Crossref
Gilbert Lazarus, Refael Alfa Budiman & Ikhwan Rinaldi. (2021) Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis. Cancer Immunology, Immunotherapy 71:2, pages 373-386.
Crossref
Mengni Guo, Jieying Liu, Ruoyu Miao, Zohaib Ahmed, James Yu, Jian Guan, Sarfraz Ahmad, Shuntai Zhou, Angela Grove, Manoucher Manoucheri, Mark A. Socinski & Tarek Mekhail. (2022) A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors. Journal of Immunotherapy Publish Ahead of Print.
Crossref
Krzysztof Laudanski, Tony Okeke, Jihane Hajj, Kumal Siddiq, Daniel J. Rader, Junnan Wu & Katalin Susztak. (2021) Longitudinal urinary biomarkers of immunological activation in covid-19 patients without clinically apparent kidney disease versus acute and chronic failure. Scientific Reports 11:1.
Crossref
Naohiro Oda, Keiji Miyoshi, Daisuke Morichika, Yuka Beika, Takahiro Taki, Reo Mitani, Toshiaki Okada & Ichiro Takata. (2021) Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir. Clinical Case Reports 9:7.
Crossref
Ravikanth Reddy. (2021) Imaging diagnosis of bronchogenic carcinoma (the forgotten disease) during times of COVID-19 pandemic: Current and future perspectives. World Journal of Clinical Oncology 12:6, pages 437-457.
Crossref
Melissa Bersanelli & Camillo Porta. (2021) Impact of SARS-CoV-2 Pandemic on Kidney Cancer Management. Kidney Cancer 5:2, pages 93-106.
Crossref
Krzysztof Laudanski, Hajj Jihane, Brook Antalosky, Danyal Ghani, Uyen Phan, Ruth Hernandez, Tony Okeke, Junnan Wu, Daniel Rader & Katalin Susztak. (2021) Unbiased Analysis of Temporal Changes in Immune Serum Markers in Acute COVID-19 Infection With Emphasis on Organ Failure, Anti-Viral Treatment, and Demographic Characteristics. Frontiers in Immunology 12.
Crossref
Carlo Augusto Mallio, Andrea Napolitano, Gennaro Castiello, Francesco Maria Giordano, Pasquale D'Alessio, Mario Iozzino, Yipeng Sun, Silvia Angeletti, Marco Russano, Daniele Santini, Giuseppe Tonini, Bruno Beomonte Zobel, Bruno Vincenzi & Carlo Cosimo Quattrocchi. (2021) Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis. Cancers 13:4, pages 652.
Crossref
Angelo Dipasquale, Pasquale Persico, Elena Lorenzi, Daoud Rahal, Armando Santoro & Matteo Simonelli. (2021) COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report. Journal for ImmunoTherapy of Cancer 9:2, pages e001870.
Crossref
Stephanie Feldman, Kristine Jang, Dylana Smith & Robert S. Copeland-Halperin. 2021. Atlas of Imaging in Cardio-Oncology. Atlas of Imaging in Cardio-Oncology 291 306 .
Vickie R. Shannon, Ronald Anderson, Ada Blidner, Jennifer Choi, Tim Cooksley, Michael Dougan, Ilya Glezerman, Pamela Ginex, Monica Girotra, Dipti Gupta, Douglas B. Johnson, Maria E. Suarez-Almazor & Bernardo L. Rapoport. (2020) Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Supportive Care in Cancer 28:12, pages 6145-6157.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.